一滴血10分钟内可评估患者是否有心脏病?我没骗你

2016-06-04 QQduhq 译 MedSci原创

仅通过一滴血便可通过一个设备在10分钟检测患者是否出现心脏病发作。该设备通过检测患者心肌肌钙蛋白I(cTnI)水平从而评估患者是否患有心脏病。它所提供的现场测试结果比实验室获得的数据更及时更有助于医生决定治疗方案和调整药物用量。 急诊就诊的病人若出现胸痛,则可以立即使用该设备进行测试,结合病人出现的症状和既往病史可迅速确立诊断,这极大减少了医生的评估和问诊时间。同时可减轻患者的痛苦,提高医生的医疗

仅通过一滴血便可通过一个设备在10分钟内检测患者是否出现心脏病发作。该设备通过检测患者心肌肌钙蛋白I(cTnI)水平从而评估患者是否患有心脏病。它所提供的现场测试结果比实验室获得的数据更及时更有助于医生决定治疗方案和调整药物用量。 


急诊就诊的病人若出现胸痛,则可以立即使用该设备进行测试,结合病人出现的症状和既往病史可迅速确立诊断,这极大减少了医生的评估和问诊时间。同时可减轻患者的痛苦,提高医生的医疗救治技术,同时提高了患者和家属的满意度,改善了医患关系。 

目前的心肌梗死诊断指南要求90%的急性突发胸痛患者血液生物标志物(心肌肌钙蛋白)检测结果阳性,但通过心电图(ECG)不能确立心肌梗死诊断。 

Paul博士指出,血液样本通常是在医院的实验室进行分析,若医生想拿到检查结果至少需要一个多小时。使用该设备快速检测可以极大地帮助减少周转时间。对高度怀疑心脏病的患者(如急性冠脉综合征患者),快速分类和快速开始治疗是至关重要的,可改善病人的预后并提高他们的生存率。只有10%的胸痛患者可以通过使用心电图诊断,其余需要依靠血样本检测心脏标志物确立心肌梗死诊断。 

医生经常需要等待6个小时,才能决定病人是否可以安全地出院或转入心内科进行进一步治疗。使用Minicare cTnI可以将时间缩短3小时。Minicare I-20旨在帮助医务工作者减少治疗时间并提高病人的存活率,从而帮助减少急诊科的拥挤程度,更好地利用医院资源。 

飞利浦公司已经开发出Minicare I-20用于多项血液测试。每个血液测试有专门的软件支持。最快几分钟便可显示抽血结果。飞利浦公司的Minicare I-20已经开始在英国、德国、荷兰和比利时出售。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=146124, encodeId=843614612400, content=谢谢谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Oct 11 22:41:29 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122124, encodeId=9b4d122124d2, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 09:01:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105789, encodeId=cf63105e8909, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 21:45:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105588, encodeId=8b01105588a7, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 14:25:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89044, encodeId=75b08904459, content=很有前景,我司有客户在用我的代理的材料在研发中, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92fb1733887, createdName=穿戴医疗功能材料商, createdTime=Wed Jun 08 16:45:00 CST 2016, time=2016-06-08, status=1, ipAttribution=)]
    2016-10-11 1e0ece0dm09(暂无匿称)

    谢谢谢谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=146124, encodeId=843614612400, content=谢谢谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Oct 11 22:41:29 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122124, encodeId=9b4d122124d2, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 09:01:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105789, encodeId=cf63105e8909, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 21:45:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105588, encodeId=8b01105588a7, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 14:25:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89044, encodeId=75b08904459, content=很有前景,我司有客户在用我的代理的材料在研发中, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92fb1733887, createdName=穿戴医疗功能材料商, createdTime=Wed Jun 08 16:45:00 CST 2016, time=2016-06-08, status=1, ipAttribution=)]
    2016-09-11 1e10c84am36(暂无匿称)

    己拜读,受益匪浅

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=146124, encodeId=843614612400, content=谢谢谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Oct 11 22:41:29 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122124, encodeId=9b4d122124d2, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 09:01:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105789, encodeId=cf63105e8909, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 21:45:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105588, encodeId=8b01105588a7, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 14:25:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89044, encodeId=75b08904459, content=很有前景,我司有客户在用我的代理的材料在研发中, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92fb1733887, createdName=穿戴医疗功能材料商, createdTime=Wed Jun 08 16:45:00 CST 2016, time=2016-06-08, status=1, ipAttribution=)]
    2016-08-27 李东泽

    这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=146124, encodeId=843614612400, content=谢谢谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Oct 11 22:41:29 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122124, encodeId=9b4d122124d2, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 09:01:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105789, encodeId=cf63105e8909, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 21:45:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105588, encodeId=8b01105588a7, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 14:25:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89044, encodeId=75b08904459, content=很有前景,我司有客户在用我的代理的材料在研发中, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92fb1733887, createdName=穿戴医疗功能材料商, createdTime=Wed Jun 08 16:45:00 CST 2016, time=2016-06-08, status=1, ipAttribution=)]
    2016-08-27 李东泽

    这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=146124, encodeId=843614612400, content=谢谢谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Oct 11 22:41:29 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122124, encodeId=9b4d122124d2, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 09:01:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105789, encodeId=cf63105e8909, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 21:45:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105588, encodeId=8b01105588a7, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 14:25:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89044, encodeId=75b08904459, content=很有前景,我司有客户在用我的代理的材料在研发中, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92fb1733887, createdName=穿戴医疗功能材料商, createdTime=Wed Jun 08 16:45:00 CST 2016, time=2016-06-08, status=1, ipAttribution=)]
    2016-06-08 穿戴医疗功能材料商

    很有前景,我司有客户在用我的代理的材料在研发中

    0

相关资讯

Nat Commun:虚拟心脏能减少心脏病发病

本周《自然—通讯》上发表的一项研究显示,遭受了心脏病的患者可以通过心脏的个性化电脑模型评估下一次出现心律失常的风险。心律失常是一种可以危及生命的心脏不规则跳动。这些3D电脑模型可以识别高风险的病人,从而让这些病人意识到自己可能需要做手术植入心脏除颤器。 尽管心律失常导致的心源性猝死是发达国家首要的死亡原因之一,现有的识别高风险患者的方法没有考虑到患者心脏几何形状的具体差异,从而治疗效果有限。

Circulation:心脏病发作不一定有典型症状

近期发表在《Circulation》上的一项新研究表明,无症状性心脏病同样具有致命性,并不是所有心脏病发作都会出现胸痛或者其他一些典型症状。众所周知,心脏病发作的典型表现为胸闷,胸部压榨样疼痛等,有的还会出现肩部、尚志、脖子、背部、牙齿、下颌痛。胃疼、气短、头晕、出汗、恶心、和焦虑也属于常见症状。而事实上,大约半数的患者心脏病发作时不会出现上诉典型症状,但流向心脏营养心肌的血液却在减少,出现心肌缺

心脏病药物迎来重磅炸弹,人类基因组数据淘金时代已经开启了

据世界卫生组织2015年的统计数据,『心血管疾病是全球的头号死因,估计在2012年有1750万人死于心血管疾病,占全球死亡总数的31%。这些死者中,估计740万人死于冠心病,670万人死于中风。』 由于市场的治疗需求巨大,众多的药企都在开展心血管疾病药物的研发。5月18日,制药巨头安进(Amgen)全资收购的子公司deCODE genetics,在医学四大期刊之一的《新英格兰医学杂志》发表文

PLoS One:当天心脏病急诊入院与硫化氢暴露相关

背景:高浓度的硫化氢(H2S)暴露导致不良的健康影响是众所周知的,但低浓度的影响还没有得到深入的研究。本研究旨在研究模拟环境间歇低浓度硫化氢(H2S)与因心脏病(HD)、呼吸系统疾病和脑卒中的相关性。方法:这项研究是以人群为基础,使用2007年1月到2014年月30号期间,雷克雅未克首都地区急诊护理机构的患者和人口登记记录的数据。研究人群为生活在雷克雅未克首都地区18岁以上个人。附近的地热发电厂排

OCC 2016:第十届东方心脏病学会议日程抢先看!

第十届东方心脏病学会议(The  10th  Oriental Congress of Cardiology,OCC 2016)将于 2016 年 5 月 26-29 日在上海世博中心(浦东新区世博大道 1500 号) 召开。尊敬的各位专家,各位同道:  秉承“开拓、进取、求真、务实”的八字方针,传承“开放、合作、创新(Open、Cooperation、Creative)”的会

家务事易让女性患心脏病

做家务事代价高。女性可能比男性更易罹患心脏病,因为她们需要做更多家务、照顾孩子以及亲属。 患有心脏病的女性比男性更容易出现严重症状,且死亡风险更高。一直以来,科学家很难确定其中的原因是因为生物学还是生活方式的差异性造成的。但是一项分离生理和社会因素的研究表明,照顾孩子以及做杂乱的家务事比生物学因素带来的差异性更大。 在全世界范围内,心脏病导致的死亡率比其他疾病均更高。医生很早以前就